001     310292
005     20260305150900.0
024 7 _ |a 10.1016/j.canlet.2026.218389
|2 doi
024 7 _ |a pmid:41780845
|2 pmid
024 7 _ |a 0304-3835
|2 ISSN
024 7 _ |a 1872-7980
|2 ISSN
037 _ _ |a DKFZ-2026-00515
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Cidre-Aranaz, Florencia
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a cIAP1 inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772719728_1921028
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B410#LA:B410# / epub
520 _ _ |a Ewing sarcoma (EwS) is a highly aggressive pediatric malignancy driven by EWSR1::ETS fusion oncoproteins -primarily EWSR1::FLI1- which deregulate genes essential for differentiation, proliferation, and cell survival. To uncover key downstream targets of this fusion involved in cell differentiation, we combined transcriptomic profiling of EwS cell lines following EWSR1::FLI1 inhibition with gene ontology analysis, a clinically annotated gene expression dataset derived from EwS patient material and network analyses. This integrative approach identified inhibitor of apoptosis protein 1 (cIAP1, alias BIRC2) as an EWSR1::FLI1-suppressed gene. Despite its known oncogenic role in many cancers, cIAP1 showed minimal expression in EwS. Using inducible cIAP1 re-expression models in EwS cells, we demonstrated that cIAP1 re-expression suppresses proliferation, clonogenic growth, and 3D spheroid formation in vitro. Transcriptomic and proteomic analyses revealed that low cIAP1 expression enhances proliferation-related gene signatures, which are inhibited upon cIAP1 re-expression. In vivo xenograft models revealed that cIAP1 re-expression significantly reduces tumor growth, mitotic activity, and Ki-67 positivity, while increasing tumor necrosis and apoptosis. These findings highlight an unexpected tumor-suppressive role for cIAP1 in fusion-driven sarcomas, contrasting with its pro-survival function in other cancers. Collectively, our results identify cIAP1 as a prognostically relevant, EWSR1::FLI1-regulated hub whose re-expression disrupts tumor progression, offering a potential therapeutic strategy to restore tumor-suppressive pathways in EwS.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a BIRC2
|2 Other
650 _ 7 |a Ewing sarcoma
|2 Other
650 _ 7 |a apoptosis
|2 Other
650 _ 7 |a cIAP1
|2 Other
650 _ 7 |a pediatric sarcoma
|2 Other
700 1 _ |a Geyer, Florian H
|0 P:(DE-He78)824510670ec489266e6e294c4f8b0e6c
|b 1
|u dkfz
700 1 _ |a Hölting, Tilman
|0 P:(DE-He78)950b74cdfed452da91ceefd57d110764
|b 2
700 1 _ |a Hanssen, Kimberley M
|0 P:(DE-He78)10e529acefa6ce98a57e02e2fddab48f
|b 3
|u dkfz
700 1 _ |a Faehling, Tobias
|0 P:(DE-He78)40245f2168b87c014e445cabf610fd46
|b 4
|u dkfz
700 1 _ |a Ritter, Alina
|0 P:(DE-He78)92c7abef8ab1c49cda71bfafccee3fdb
|b 5
|u dkfz
700 1 _ |a Zimmermann, Malenka
|0 P:(DE-He78)8746c92b0303748b84d9cf25912aa9fd
|b 6
|u dkfz
700 1 _ |a Mao, Lianghao
|0 P:(DE-He78)507c97fafa917642c6757c53a3ca3383
|b 7
|u dkfz
700 1 _ |a Alonso, Javier
|b 8
700 1 _ |a Sastre, Ana
|b 9
700 1 _ |a Jayavelu, Ashok Kumar
|0 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
|b 10
|u dkfz
700 1 _ |a Knott, Maximilian M L
|0 P:(DE-He78)ddba8e300cae44b1021c9b65192fdb36
|b 11
|u dkfz
700 1 _ |a Musa, Julian
|0 P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41
|b 12
|u dkfz
700 1 _ |a Grünewald, Thomas
|0 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
|b 13
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.canlet.2026.218389
|g p. 218389 -
|0 PERI:(DE-600)2004212-7
|p nn
|t Cancer letters
|v nn
|y 2026
|x 0304-3835
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)824510670ec489266e6e294c4f8b0e6c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)950b74cdfed452da91ceefd57d110764
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)10e529acefa6ce98a57e02e2fddab48f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)40245f2168b87c014e445cabf610fd46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)92c7abef8ab1c49cda71bfafccee3fdb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)8746c92b0303748b84d9cf25912aa9fd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)507c97fafa917642c6757c53a3ca3383
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)ddba8e300cae44b1021c9b65192fdb36
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2026
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER LETT : 2022
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER LETT : 2022
|d 2025-11-12
920 2 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)A400-20160331
|k A400
|l KKE Pädiatrische Leukämie
|x 2
920 0 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B410-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)A400-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21